SALT LAKE CITY – July 30, 2024 – bioMérieux, a world leader in in vitro diagnostics, received 10 IMV ServiceTrak™ Clinical Laboratory Awards today in the categories of microbial identification (ID) and susceptibility testing (AST), Blood Culture, Immunoassay, and Molecular Diagnostics. The awards symbolize bioMérieux’s high-quality comprehensive customer service and system performance.
IMV, part of Science and Medicine Group, is a market research and business intelligence provider to the laboratory diagnostic industry. IMV ServiceTrak Clinical Awards are presented yearly to manufacturers with the highest satisfied responses, representing the best customer satisfaction, performance, and service.
At the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Conference, bioMérieux accepted the 10 awards across ID/AST, Blood Culture, Immunoassay, and Molecular Diagnostics categories in which laboratory professionals rated bioMérieux technology platforms, system performance and service to be the best in the following categories:
ID/AST Systems 2024
- Best Customer Satisfaction
- Best System Performance
- Best OEM Service Performance
Blood Culture Systems 2024
- Best Customer Satisfaction
- Best System Performance
- Best OEM Service Performance
Immunoassay Analyzers 2024
- Best Customer Satisfaction
- Best System Performance
- Best OEM Service Performance
Molecular Diagnostics 2024
- Best OEM Service Performance (tied)
“These awards are a direct result of the persistent and tireless focus of our entire organization, especially our manufacturing and research and development team members,” said bioMérieux's David Machenaud, Vice President, Customer Support Operations, U.S. Customer Service. “We provide extensive training to our team members to ensure exceptional service and customer centricity, which is engrained into bioMérieux’s culture. We are honored to be recognized with IMV ServiceTrak awards for seven consecutive years.”
The accolades embody bioMérieux’s commitment to public health, providing innovative diagnostic testing solutions and fast, accurate, and actionable data to aid physicians in diagnosing, treating, and caring for patients.
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2023, revenues reached €3.7 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products. www.biomerieux.com.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP